Logistic regression model for predicting failure of dual antihypertensive therapy: a prospective comparative non-randomized clinical trial
-
Published:2023-10-05
Issue:5
Volume:30
Page:54-63
-
ISSN:2541-9544
-
Container-title:Kuban Scientific Medical Bulletin
-
language:
-
Short-container-title:Kuban. nauсh. med. vestnik
Author:
Okorokova T. O.1ORCID, Kryuchkova O. N.2ORCID
Affiliation:
1. N.I. Pirogov Kerch Hospital No. 1 2. Georgievsky Medical Academy of Vernadsky Crimean Federal University
Abstract
Background. Initial dual antihypertensive therapy is currently considered as the first management step for the majority of patients with arterial hypertension. However, it often fails to achieve the target blood pressure levels. An approved algorithm for predicting the failure of dual antihypertensive therapy is still to be developed. Objectives. To establish predictors of dual antihypertensive therapy failure in patients with high and very high cardiovascular risk and to create a model for predicting negative outcome of dual antihypertensive therapy. Methods. The paper presents a prospective comparative non-randomized clinical trial. The recruiting of participants and recording of results were carried out in March–December 2019 with 3 months of the follow-up period. The trial involved examination of 88 patients with poor blood pressure control, stage II and III arterial hypertension, high and very high cardiovascular risk of stages 1–3. Clinical and laboratory examination was carried out in compliance with the current regulatory documents. Additional examination included tests for uric acid, high-sensitivity C-reactive protein, as well as respiratory polygraphy and computerized capillaroscopy. All patients were prescribed dual antihypertensive therapy. The primary search for predictors was performed using the binary logistic regression. The predictive model was developed by stepwise variable selection. The diagnostic significance of the binary classifier was assessed by means of ROC-curve analysis; the calculation was performed using MedCalc 20.218 software (MedCalc Software Ltd., Belgium). Results. Administration of two hypotensive drugs appears to be effective in 33% of patients. The final model for predicting negative outcomes of dual antihypertensive therapy included such independent predictors as interventricular septal thickness, daily mean systolic blood pressure, and area density of the capillary network. The odds ratio accounted for 9.1 (95% confidence interval 3.12; 26.82). The area under the ROC curve based on the multiple binary logistic regression model comprised 0.805±0.05 with 95% confidence interval: 0.707-0.882 (p<0.0001). The sensitivity and specificity of the method amounted to 83.1 and 69.0%, respectively. The prediction accuracy comprised 77.3%. Conclusion. The development of patient-oriented algorithms for selection of hypotensive treatment is considered to be essential due to poor blood pressure control during dual antihypertensive therapy. The developed prognostic model may be applied when managing hypertension.
Publisher
Kuban State Medical University
Reference20 articles.
1. Kobalava ZD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI, Barbarash OL, Boitsov SA, Vavilova TV, Villevalde SV, Galyavich AS, Glezer MG, Grineva EN, Grinstein YuI, Drapkina OM, Zhernakova YuV, Zvartau NE, Kislyak OA, Koziolova NA, Kosmacheva ED, Kotovskaya YuV, Libis RA, Lopatin YuM, Nebiridze DV, Nedoshivin AO, Ostroumova OD, Oschepkova EV, Ratova LG, Skibitsky VV, Tkacheva ON, Chazova IE, Chesnikova AI, Chumakova GA, Shalnova SA, Shestakova MV, Yakushin SS, Yanishevsky SN. Arterial hypertension in adults Clinical guidelines 2020 Russian Journal of Cardiology 2020;25(3):3786 (In Russ.). https://doi.org/1015829/15604071-2020-3-3786 2. Caraballo C, Desai NR, Mulder H, Alhanti B, Wilson FP, Fiuzat M, Felker GM, Piña IL, O’Connor CM, Lindenfeld J, Januzzi JL, Cohen LS, Ahmad T. Clinical Implications of the New York Heart Association Classification. J Am Heart Assoc. 2019;8(23):e014240. https://doi.org/10.1161/JAHA.119.014240 3. 2018 ESC/ESH Guidelines for the management of arterial hypertension Rev Esp Cardiol (Engl Ed) 2019;72(2):160. https://doi.org/101016/jrec201812004 4. Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Weber MA, Williams B, Yusuf S. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet 2017;389(10085):2226–2237. https://doi.org/101016/S01406736(17)30754-7 5. Whelton PK, Flack JM, Jennings G, Schutte A, Wang J, Touyz RM. Editors’ Commentary on the 2023 ESH Management of Arterial Hypertension Guidelines. Hypertension. 2023;80(9):1795–1799. https://doi.org/10.1161/HYPERTENSIONAHA.123.21592
|
|